NASDAQ · PAHC
Healthcare · Drug Manufacturers - Specialty & Generic
$35.03
Up+$0.76 (+2.17%)
Updated Sep 16, 2026, 5:18 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PAHC closed at $35.03 after 20 trading sessions, up 1.10% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $36.00 | $36.00 | $34.94 | $35.03 | 322.82K |
| Sep 14, 2026 | $35.92 | $36.70 | $35.835 | $35.94 | 258.36K |
| Sep 11, 2026 | $36.99 | $37.66 | $35.51 | $35.62 | 212.3K |
| Sep 10, 2026 | $36.80 | $36.96 | $36.295 | $36.58 | 174.06K |
| Sep 9, 2026 | $37.11 | $37.4599 | $36.60 | $36.80 | 176.89K |
| Sep 8, 2026 | $37.92 | $37.92 | $36.86 | $37.31 | 182.19K |
| Sep 4, 2026 | $38.26 | $38.82 | $37.685 | $38.25 | 176.42K |
| Sep 3, 2026 | $40.24 | $40.50 | $38.20 | $38.58 | 174.64K |
| Sep 2, 2026 | $38.32 | $40.65 | $38.32 | $39.92 | 324.24K |
| Sep 1, 2026 | $37.77 | $38.72 | $37.63 | $38.37 | 370.17K |
| Aug 31, 2026 | $37.13 | $38.07 | $36.7239 | $37.74 | 357.38K |
| Aug 28, 2026 | $36.36 | $38.65 | $36.36 | $37.67 | 362.75K |
| Aug 27, 2026 | $39.39 | $39.39 | $35.01 | $36.35 | 432.91K |
| Aug 26, 2026 | $36.48 | $36.79 | $35.735 | $36.09 | 300.6K |
| Aug 25, 2026 | $35.71 | $36.105 | $35.30 | $35.93 | 236.8K |
| Aug 24, 2026 | $36.32 | $36.735 | $35.105 | $35.31 | 153.19K |
| Aug 21, 2026 | $35.41 | $36.44 | $35.29 | $36.32 | 324.42K |
| Aug 20, 2026 | $35.26 | $35.89 | $34.63 | $35.18 | 179.33K |
| Aug 19, 2026 | $35.00 | $36.12 | $35.00 | $35.44 | 163.1K |
| Aug 18, 2026 | $34.92 | $35.09 | $34.20 | $34.65 | 89.3K |
The latest Smart Investors Daily articles mentioning PAHC.
PAHC research
Company profile and research snapshot.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 14, 2026 | Citigroup | Neutral | — |
| Apr 15, 2026 | Citigroup | Neutral | — |
| Nov 7, 2025 | JP Morgan | Overweight | — |
| Aug 29, 2025 | B of A Securities | Underperform | — |
| Jul 7, 2025 | JP Morgan | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 14, 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Phibro (PAHC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Yahoo · Sep 9, 2026
TEANECK, N.J., September 09, 2026--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference.
Yahoo · Sep 5, 2026
Phibro Animal Health earnings and guidance set the tone Phibro Animal Health (PAHC) drew investor attention after issuing earnings guidance for the fiscal year ending June 30, 2027, alongside reporting fourth quarter and full year 2026 results. The company now projects 2027 net sales of US$1.55b to US$1.60b and net income of US$122 million to US$132 million. Expected diluted EPS is US$2.98 to US$3.22. These figures follow 2026 sales of US$1,518.09 million and net income of US$99.72...
Yahoo · Sep 2, 2026
PAHC vs. LMAT: Which Stock Is the Better Value Option?
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PAHC.
